Table 4 Acute toxicity as registered during the treatment
Acute toxicity | 1 W-CDDP (N.114) | 3 W-CDDP (N.52) | χ2 | Entire series |
|---|---|---|---|---|
Whole hematol tox | 0.285 | |||
G0 | 9 (7.9%) | 1 (1.9%) | 10 (6%) | |
G1–G2 | 84 (73.7%) | 39 (75%) | 123 (74%) | |
G3–G4 | 21 (18.4%) | 12 (23.1%) | 33 (20%) | |
Anemia | 0.37 | |||
G0 | 11 (9.6%) | 6 (11.5%) | 17 (10.2%) | |
G1–G2 | 102 (89.5%) | 44 (84.6%) | 146 (88%) | |
G3–G4 | 1 (0.9%) | 2 (3.8%) | 3 (1.8%) | |
Leucopenia | 0.524 | |||
G0 | 16 (14%) | 7 (13.5%) | 23 (14%) | |
G1–G2 | 80 (70.2%) | 33 (63.5%) | 113 (68%) | |
G3–G4 | 18 (15.8%) | 12 (23.1%) | 30 (18%) | |
Thrombocytopenia | 0.01 | |||
G0 | 26 (22.8%) | 24 (46.2%) | 50 (30%) | |
G1–G2 | 85 (74.6%) | 27 (51.9%) | 112 (67.5%) | |
G3–G4 | 3 (2.6%) | 1 (1.9%) | 4 (2.5%) | |
Kidney injury | 0.111 | |||
G0 | 89 (78.1%) | 46 (88.5%) | 135 (81.4%) | |
G1–G2 | 25 (21.9%) | 6 (11.5%) | 31 (18.6%) | |
G3–G4 | ||||
Mucositis | 0.637 | |||
G0 | 2 (1.8%) | – | 2 (1.2%) | |
G1–G2 | 72 (63.2%) | 36 (69.2%) | 108 (65%) | |
G3–G4 | 39 (34.2%) | 16 (30.8%) | 55 (33.2%) | |
ND | 1 (0.9%) | – | 1 (0.6%) | |
Dermatitis | 0.067 | |||
G0 | 4 (3.5%) | – | 4 (2.5%) | |
G1–G2 | 88 (77.2%) | 48 (92.3%) | 136 (81.9%) | |
G3–G4 | 14 (12.6%) | 4 (7.7%) | 18 (10.8%) | |
ND | 8 (7%) | – | 8 (4.8%) | |
Xerostomia | 0.009 | |||
G0 | 29 (25.4%) | 9 (17.3%) | 38 (22.9%) | |
G1–G2 | 68 (59.6%) | 43 (82.7%) | 111 (66.9%) | |
G3–G4 | 4 (3.5%) | – | 4 (2.4%) | |
ND | 13 (11.4%) | – | 13 (7.8%) | |
Dysphagia | 0.312 | |||
G0 | 18 (15.8%) | 5 (9.6%) | 23 (13.8%) | |
G1–G2 | 72 (63.2%) | 39 (75%) | 111 (66.9%) | |
G3–G4 | 24 (21.1%) | 8 (15.4%) | 32 (19.3%) | |